Tenecteplase
Revision as of 18:47, 18 December 2018 by Rossdonaldson1 (talk | contribs) (Created page with "==Administration== *Type: *Dosage Forms: *Routes of Administration: *Common Trade Names: ==Adult Dosing== ===Thrombolysis for PE=== *50 mg bolus or 0.5 mg/kg bolus <ref...")
Administration
- Type:
- Dosage Forms:
- Routes of Administration:
- Common Trade Names:
Adult Dosing
Thrombolysis for PE
Pediatric Dosing
Special Populations
Pregnancy Rating
Lactation risk
Renal Dosing
- Adult:
- Pediatric:
Hepatic Dosing
- Adult:
- Pediatric:
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
Common
Pharmacology
- Half-life:
- Metabolism:
- Excretion:
Mechanism of Action
Comments
See Also
References
- ↑ Fatovich D, Dobb G, Clugston R. A pilot randomised trial of thrombolysis in cardiac arrest (The TICA trial). Resuscitation. 2004;61(3):309-313.
- ↑ Bozeman W, Kleiner D, Ferguson K. Empiric tenecteplase is associated with increased return of spontaneous circulation and short term survival in cardiac arrest patients unresponsive to standard interventions. Resuscitation. 2006;69(3):399-406.
- ↑ Böttiger B, Arntz H, Chamberlain D, et al. Thrombolysis during resuscitation for out-of-hospital cardiac arrest. N Engl J Med. 2008;359(25):2651-2662.